文献速递传染病防控与疫情报告免疫规划

肯尼亚2023年疫情应对中2型新型口服脊灰疫苗的免疫原性:观察性队列研究

Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study.
PubMed 文献 · Vaccine · 2026-08-28

该观察性队列研究在肯尼亚Kitui和Tana River县纳入6-59月龄儿童,评估疫情应对中接种一剂和两剂nOPV2的免疫原性。主要终点为两剂后累积免疫应答,结果显示两剂后62%(95%CI 57-66)的参与者产生2型免疫应答,提示两剂nOPV2在撒哈拉以南非洲2型脊灰野病毒疫情应对中可能不足以达到高人群免疫。

要点

  • 两剂nOPV2后62%(95%CI 57-66)的儿童产生2型免疫应答。
  • 一剂nOPV2后43%(95%CI 38-47)的儿童产生2型免疫应答。
  • 2型血清阳性率从入组时19%升至两剂后72%。

核心结论

  • 两剂nOPV2在疫情应对中仅使62%的儿童产生2型免疫应答,可能不足以实现高人群免疫。

主要发现

  • 475名参与者中461名(97%)完成所有访视并纳入分析。
  • 两剂nOPV2后4周,461名参与者中285名(62%;95%CI 57-66)观察到累积2型免疫应答。
  • 一剂nOPV2后,461名参与者中196名(43%;95%CI 38-47)观察到2型免疫应答。
  • 2型血清阳性率(滴度≥1:8)从入组时19%增至两剂nOPV2后72%。

临床怎么用

  • 在2型脊灰野病毒疫情应对中,两剂nOPV2可能不足以达到高人群免疫,需考虑补充免疫策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2023, novel oral polio vaccine type 2 (nOPV2) was used to respond to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Kenya. We assessed the immunogenicity of one and two doses of nOPV2 administered during outbreak response. METHODS: An observational cohort study was conducted from October to December 2023 in Kitui and Tana River counties in Kenya. Children aged 6-59 months were enrolled. Two nOPV2 doses were administered. Dried blood spots (DBS) were collected at enrollment, four-weeks after the first nOPV2 dose, and two- and four-weeks after the second nOPV2 dose. The DBS cards were tested at the US Centers for Disease Control and Prevention (CDC), Atlanta for the presence of poliovirus neutralizing antibodies using microneutralization assays. The primary endpoint was cumulative immune response after two nOPV2 doses. FINDINGS: Of the 475 participants followed in the study, 461 (97%) completed all study visits and were included in the analysis. Four weeks after two nOPV2 doses, a cumulative type 2 immune response was observed in 285 (62%; 95% CI 57-66) of 461 participants. After one nOPV2 dose, type 2 immune response was observed in 196 (43%, 95% CI 38-47) of 461 participants. Type 2 seropositivity (titers ≥1:8) increased from 19% at enrollment to 72% after two nOPV2 doses. INTERPRETATION: The study demonstrated an immune response in 62% of the participants following two nOPV2 outbreak vaccination rounds. These findings suggest that two nOPV2 doses may be insufficient to achieve high population immunity during poliovirus type 2 outbreak response in sub-Saharan Africa.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Anand A, Jepkosgei D, Mwachari C, et al. Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study. Vaccine. 2026. PMID: 42664529. doi:10.1016/j.vaccine.2026.128969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。